MOVANTIK

This brand name is authorized in United States. It is also authorized in Canada, New Zealand.

Active ingredients

The drug MOVANTIK contains one active pharmaceutical ingredient (API):

1	Naloxegol UNII 65I14TNM33 - NALOXEGOL OXALATE
	Naloxegol is a PEGylated derivative of the mu-opioid receptor antagonist naloxone. PEGylation reduces naloxegol’s passive permeability and also renders the compound a substrate for the P-glycoprotein transporter. Naloxegol functions as a peripherally-acting mu-opioid receptor antagonist in the gastrointestinal tract, thereby decreasing the constipating effects of opioids without impacting opioid-mediated analgesic effects on the central nervous system.
	Read more about Naloxegol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MOVANTIK Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A06AH03		A Alimentary tract and metabolism → A06 Laxatives → A06A Laxatives → A06AH Peripheral opioid receptor antagonists
Discover more medicines within A06AH03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02442167, 02442175
NZ	Medicines and Medical Devices Safety Authority	18231, 18232
US	FDA, National Drug Code	0310-1969, 0310-1970, 55700-383, 57841-1300, 57841-1301